汉密尔顿抑郁量表
萧条(经济学)
评定量表
完全缓解
心理学
重性抑郁障碍
内科学
精神科
医学
儿科
化疗
心情
发展心理学
宏观经济学
经济
作者
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,M.B.A. Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeïm,David J. Kupfer,James F. Luther,Maurizio Fava
标识
DOI:10.1176/ajp.2006.163.11.1905
摘要
This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of or=11 (HRSD(17)>or=14) defined relapse.The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps.When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI